Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents

Radiation therapy (RT) and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors mediate poorly overlapping cytostatic and immunostimulatory effects, suggesting that combinatorial regimens may enable supra-additive tumor control. Our preclinical findings demonstrate that administration schedule stands out...

Descripción completa

Detalles Bibliográficos
Autores principales: Petroni, Giulia, Galluzzi, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899633/
https://www.ncbi.nlm.nih.gov/pubmed/33659100
http://dx.doi.org/10.1080/2162402X.2021.1889101
_version_ 1783654059554635776
author Petroni, Giulia
Galluzzi, Lorenzo
author_facet Petroni, Giulia
Galluzzi, Lorenzo
author_sort Petroni, Giulia
collection PubMed
description Radiation therapy (RT) and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors mediate poorly overlapping cytostatic and immunostimulatory effects, suggesting that combinatorial regimens may enable supra-additive tumor control. Our preclinical findings demonstrate that administration schedule stands out as a major determinant of efficacy when RT and CDK4/6 inhibitors are combined for breast cancer therapy.
format Online
Article
Text
id pubmed-7899633
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-78996332021-03-02 Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents Petroni, Giulia Galluzzi, Lorenzo Oncoimmunology Editorial Radiation therapy (RT) and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors mediate poorly overlapping cytostatic and immunostimulatory effects, suggesting that combinatorial regimens may enable supra-additive tumor control. Our preclinical findings demonstrate that administration schedule stands out as a major determinant of efficacy when RT and CDK4/6 inhibitors are combined for breast cancer therapy. Taylor & Francis 2021-02-19 /pmc/articles/PMC7899633/ /pubmed/33659100 http://dx.doi.org/10.1080/2162402X.2021.1889101 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Editorial
Petroni, Giulia
Galluzzi, Lorenzo
Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents
title Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents
title_full Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents
title_fullStr Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents
title_full_unstemmed Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents
title_short Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents
title_sort impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899633/
https://www.ncbi.nlm.nih.gov/pubmed/33659100
http://dx.doi.org/10.1080/2162402X.2021.1889101
work_keys_str_mv AT petronigiulia impactoftreatmentscheduleontheefficacyofcytostaticandimmunostimulatoryagents
AT galluzzilorenzo impactoftreatmentscheduleontheefficacyofcytostaticandimmunostimulatoryagents

Ejemplares similares